Efficacy

Efficacy of Ketas (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Ibudilast, known commercially as Ketas, is a phosphodiesterase inhibitor that has been primarily used in the treatment of asthma and post-stroke complications. Its efficacy in Amyotrophic Lateral Sclerosis (ALS) has been explored due to its neuroprotective and anti-inflammatory properties. While research is ongoing, some studies suggest that Ibudilast may slow the progression of ALS. However, it is important to note that the drug is not currently approved for the treatment of ALS by regulatory agencies, and more robust clinical trials are needed to confirm its efficacy and safety for patients with this condition.

Current Research on Ketas (Ibudilast) for ALS

Clinical trials have been conducted to evaluate the potential benefits of Ibudilast in ALS. For instance, a phase 2 trial (ClinicalTrials.gov Identifier: NCT02238626) assessed the safety, tolerability, and preliminary efficacy of Ibudilast in people with ALS. The study measured outcomes such as changes in the ALS Functional Rating Scale-Revised (ALSFRS-R) and forced vital capacity (FVC). While initial results were promising, indicating a slower rate of disease progression, larger-scale studies are necessary to fully understand the impact of Ibudilast on ALS and to determine appropriate dosing.

Efficacy of Pheburane (Sodium Phenylbutyrate) in Amyotrophic Lateral Sclerosis (ALS)

Pheburane, the trade name for sodium phenylbutyrate, is a drug approved for the treatment of urea cycle disorders. Its role in ALS is based on its potential to reduce neuronal stress and promote neuronal survival. Research into sodium phenylbutyrate for ALS is less advanced than for some other investigational drugs, and its efficacy for this indication remains to be fully established. As with Ibudilast, sodium phenylbutyrate is not currently approved for the treatment of ALS, and its use in this context would be considered off-label.

Research and Clinical Trials Involving Pheburane (Sodium Phenylbutyrate) for ALS

Studies have investigated the combination of sodium phenylbutyrate with other compounds, such as tauroursodeoxycholic acid, to determine their synergistic effects on ALS progression. For example, a clinical trial (ClinicalTrials.gov Identifier: NCT03127514) is exploring the combination of these two drugs and their impact on disease progression and survival. The outcomes of such trials are crucial to ascertain the potential role of sodium phenylbutyrate in the treatment of ALS, and until more data is available, its efficacy in this disease remains speculative.